SLEにおける生物学的製剤のガイドラインでの立ち位置, 各製剤の効果・安全性・好適患者について

概要

本スライドの対象者

参考文献

• LANDMARK NEPHROLOGY ”lupus nephritis” https://landmarknephrology.com/topic/lupus-nephritis/

• Bertsias G Rheumatology 2024

• Kaneko K et al. Clin Transl Med 2021

• Navarra SV, et al Lancet. 2011 Feb 26;377(9767):721-31.

• Furie R et al. Arthritis Rheum. 2011 Dec;63(12):3918-30.

• Furie R, et al. N Engl J Med. 2020 Sep 17;383(12):1117-1128.

• Zhang F et al. Ann Rheum Dis. 2018 Mar;77(3):355-363.

• Sheikh SZ et al. Lancet Rheumatol. 2021 Feb;3(2):e122-e130

• Aranow C et al. Ann Rheum Dis. 2024 Oct 21;83(11):1502-1512

• Furie R, et al. Arthritis Rheumatol. 2017 Feb;69(2):376-386.

• Furie RA, et al. Lancet Rheumatol. 2019 Dec;1(4):e208-e219.

• Morand EF, et al. N Engl J Med. 2020 Jan 16;382(3):211-221.

• Kalunian KC, et al. Arthritis Rheumatol. 2023 Feb;75(2):253-265.

• Jayne D et al. Ann Rheum Dis. 2022 Apr;81(4):496-506.

• Looney RJ, et al. Arthritis Rheum. 2004 Aug;50(8):2580-9.

• Merrill JT, et al. Arthritis Rheum. 2010 Jan;62(1):222-33

• Rovin BH et al. Arthritis Rheum. 2012 Apr;64(4):1215-26

• Tanaka Y, Mod Rheumatol. 2023 Jan 3;33(1):145-153.

• Allen ME, Rus V, Szeto GL. Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies. Trends Mol Med. 2021 Feb;27(2):152-171. PMID: 33046407

• Tanaka Y. RMD Open. 2023 Aug;9(3):e003270. PMID: 37597847.

• Kirou KA et al. Front Immunol. 2022

• Allen ME, et al. Trends Mol Med. 2021 Feb;27(2):152-171

• Muller M.D et al. NEJM 20